Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2806

A Type-I Interferon Signature Is Associated with Autoantibody Profiles in Connective Tissue Diseases: Results from the Lupus Extended Autoimmune Phenotype (LEAP) Study

9:00AM-11:00AM: Abstract Number: 2829

Adherence to Treatment and Renal Transplantation Graft Failure in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2851

An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice

9:00AM-11:00AM: Abstract Number: 2841

Anti-Ro52/TRIM21 Antibodies Are Associated with QT Interval Prolongation in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2847

Antibodies to Double Stranded DNA: Combined Standard ELISA and High-Salt ELISA Assays for the Detection of SLE Disease Activity

9:00AM-11:00AM: Abstract Number: 2845

Antineutrophil Cytoplasmic Antibodies in Systemic Lupus Erythematosus: Incidence, Outcome and Prognosis

9:00AM-11:00AM: Abstract Number: 2846

Application of a Novel Anti-Nuclear Antibody Multiplex Test Using Finger Stick and Venous Whole Blood in a Rheumatology Clinic – Demonstration of Feasibility

9:00AM-11:00AM: Abstract Number: 2840

Are There Genetic Predispositions to Diffuse Large B-Cell Lymphoma (DLBCL) in Systemic Lupus (SLE)?

9:00AM-11:00AM: Abstract Number: 2831

Associations of BAFF and Anti-BAFF Autoantibodies with Disease Activity in Oriental Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2816

Broad Autoantibody Profiling in Ethnically Diverse SLE Cohorts Reveals a Set of Conserved Autoantibodies That Are Correlated to a Type I Interferon Signature

9:00AM-11:00AM: Abstract Number: 2800

Cell-Bound Complement Activation Products in Multi-Analyte Assay with Algorithm Aid the Diagnosis of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2850

Changes in Urinary Biomarker Levels Can Predict Treatment Responses in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2839

Circulating CD4+CD28null T-Cells Predict the Occurrence of New Lung Damage in Systemic Lupus Erythematosus (SLE) Patients

9:00AM-11:00AM: Abstract Number: 2812

Clinical Trial Simulation Identifies Factors for Patient Engagement in Systemic Lupus Erythematosus and Lupus Nephritis Trials By African-Americans

9:00AM-11:00AM: Abstract Number: 2819

Clinical Utility of Anti-Aquaporin 4 Antibody Measurement in Patients with Neuropsychiatric Systemic Lupus Erythematosus with Neuromyelitis Optica Spectrum Disorder Manifestations

9:00AM-11:00AM: Abstract Number: 2826

Clinical Utility of Circulating Anti-N-Methyl-D-Aspartate Receptor Subunits NR2A/B Antibody for the Diagnosis of Neuropsychiatric Syndromes in Systemic Lupus Erythematosus and Sjogren’s Syndrome: An Updated Meta-Analysis

9:00AM-11:00AM: Abstract Number: 2809

Comparative Analysis of Anti-Nuclear Antibody Testing Using Blinded Replicate Samples Reveals Variability Between Commercial Testing Laboratories

9:00AM-11:00AM: Abstract Number: 2803

Comparison of Clinical and Serological Differences According to the Autoantibody Cluster in Women with Systemic Lupus Erythematosus: Results from the Korean Lupus Network (KORNET) Registry

9:00AM-11:00AM: Abstract Number: 2815

Comparison of Lupus Nephritis Induction Therapy with Cyclophosphamide High Dose Versus Low Dose

9:00AM-11:00AM: Abstract Number: 2802

Comparison of the Clinical, Serological, and Prognostic Differences Among Juvenile-, Adult-, and Late-Onset Lupus Nephritis in Korean Patients: A Case-Control Study

9:00AM-11:00AM: Abstract Number: 2820

Comprehensive Aptamer-Based Screening of 1129 Proteins Reveals Novel Urinary Biomarkers of Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2810

Correlates of Spontaneous Cytokine Production in Individuals Undergoing Interferon-Gamma Release Assay Testing

9:00AM-11:00AM: Abstract Number: 2828

Difference of d-Dimer Between Two Time Points Predicts Prognosis of Admitted Patients with SLE Flare up

9:00AM-11:00AM: Abstract Number: 2795

Effect of Complete or Partial Proteinuria Recovery Compared to No Recovery at 2 Years after the Diagnosis of Lupus Nephritis on Long Term Outcomes

9:00AM-11:00AM: Abstract Number: 2818

High Sensitivity Multiplex ELISA Reveals Cytokine Expression Heterogeneity in Active SLE

9:00AM-11:00AM: Abstract Number: 2838

Histopatholgic Predictors of Poor Renal Outcomes in a Multi-Ethnic Cohort

9:00AM-11:00AM: Abstract Number: 2792

Hyperhomocysteinemia in SLE

9:00AM-11:00AM: Abstract Number: 2817

Identification of Subsets of Systemic Lupus Erythematosus Patients By Principal Component Analysis and Urine Biomarkers

9:00AM-11:00AM: Abstract Number: 2814

Immunofluorescence Pattern and Titer of the Antinuclear Antibody Test Correlate with Disease Activity in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2844

Immunoglobulins Level and Risk of Infection in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2837

Importance of Mixed Speckled/ Homogeneous DFS70 ANA Patterns

9:00AM-11:00AM: Abstract Number: 2821

Is Hyperuricemia an Independent Risk Factor for Arterial Thrombosis in Systemic Lupus Erythematosus?

9:00AM-11:00AM: Abstract Number: 2854

Laboratory and Demographic Longitudinal Profile of a Large Cohort of Individuals Presenting with the ANA Nuclear Dense Fine Speckled Immunofluorescence Pattern

9:00AM-11:00AM: Abstract Number: 2824

Lack of Partial Renal Response By 12 Weeks after Induction Therapy Is an Indicator to Switch the Treatment in Lupus Nephritis Class III or IV for Reducing Future Damage Accrual

9:00AM-11:00AM: Abstract Number: 2852

Long Term Prognosis of Lupus Nephritis in the Afro-Caribbean Population of Martinique with Free Access to Healthcare

9:00AM-11:00AM: Abstract Number: 2835

Longitudinal Analysis of Th1 and Th2 Cytokines in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2833

Low Plasma Concentrations of Apolipoprotein M Correlate to Disease Activity and Endothelial Dysfunction in SLE

9:00AM-11:00AM: Abstract Number: 2796

Low Versus High Dose Glucocorticosteroid Used in Lupus Nephritis: Is There a Difference

9:00AM-11:00AM: Abstract Number: 2836

Microparticles of Endothelial Origin in Women with Systemic LUPUS Erythematosus UNDER Treatment

9:00AM-11:00AM: Abstract Number: 2798

Multi-Center Validation of Platelet Bound C4d, a Biomarker for Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2848

Near Patient Anti-Nuclear Antibody Multiplex Testing Using Whole Blood for the Diagnosis of Connective Tissue Diseases in a Tertiary Care Center

9:00AM-11:00AM: Abstract Number: 2853

Neutrophilia in Systemic Lupus Erythematosus As a Potential Indicator of Disease Activity

9:00AM-11:00AM: Abstract Number: 2830

Non-Calcified Coronary Artery Plaque Associates with Adverse Lipoprotein Profiles in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2832

Novel Gene Variants Associated with Cardiovascular Disease in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2799

Outcomes in Patients with Early and Delayed Onset Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2805

Outcomes of Lupus Nephritis Patients Following Discontinuation of Treatment

9:00AM-11:00AM: Abstract Number: 2842

Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2801

Predictors of Incident Episodes of Proteinuria Among Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2811

Predictors of Persistent Disease Activity and Persistent Remission in Systemic Lupus Erythematosus – Results from the Hopkins Lupus Cohort

9:00AM-11:00AM: Abstract Number: 2804

Predictors of Survival in Renal Transplantation for Lupus Nephritis – 40 Patients in 40 Years

9:00AM-11:00AM: Abstract Number: 2843

Prevalence of Anti-DFS70 Antibodies in Patients with and without Systemic Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2827

Prognostic Significance of Repeat Biopsy in Lupus Nephritis: Histopathologic Worsening Is an Independent Risk Factor for End Stage Renal Disease and Death

9:00AM-11:00AM: Abstract Number: 2797

Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2857

Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles

9:00AM-11:00AM: Abstract Number: 2813

Risk of Renal Failure within 10 or 20 Years of SLE Diagnosis, By Patient Characteristics

9:00AM-11:00AM: Abstract Number: 2808

Role of Serum Autoantibodies in Blood Brain Barrier Damages in Neuropsychiatric Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 2822

Serum 25-Hydroxyvitamin D3 Levels and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis

9:00AM-11:00AM: Abstract Number: 2856

Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms

9:00AM-11:00AM: Abstract Number: 2807

Skin and Muscle Sodium Concentrations in Patients with Systemic Lupus Erythematosus: A Proof of Concept Study

9:00AM-11:00AM: Abstract Number: 2794

Sustained Complete Remission in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2849

Systemic Lupus Erythematosus Patients with Antibodies Against U1-Ribonucleoprotein Exhibit a Specific Pattern of Disease Manifestations

9:00AM-11:00AM: Abstract Number: 2855

The Long-Term Clinical Outcomes of Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2793

The Predictors of Sustained Complete Remission in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2823

Urinary Angiostatin, CXCL4 and VCAM-1 As Biomarkers for Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2825

Urinary BAFF and APRIL Levels: Potential Biomarkers of Active Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2858

Urinary PF4 and E-Selectin As Novel Biomarkers for Disease Activity and Renal Damage in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 2834

Utility of the Brain Perfusion Single Photon Emission Computed Tomography in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].